Please assess the completion status of the following clinical trial:

Trial Title: Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria (4 of 11 ACR criteria),~* 2. SLEDAI ≥4 and ≤10,~* 3. Positive Anti-nuclear Antibodies (ANA) and/or Positive anti-dsDNA antibodies~* 4. Male or female between 18 and 50 years of age~* 5. Current immunity to measles, mumps, rubella and varicella, as evidenced by positive IgG titers at the time of screening,~* 6. For subjects recruited during local influenza season, current vaccination against seasonal influenza at least 7 days prior to randomization,~* 7. Vaccination against H1N1 influenza at least 7 days prior to randomization.~* 8. For subjects with reproductive potential (males and females), use of a reliable means of contraception~* 9. Written informed consent obtained from the subject.~Exclusion Criteria:~* 1. Any serious manifestation of lupus at entry, that, in the opinion of the investigator is likely to require initiation of off-protocol medication changes during the course of the study and in particular no BILAG A score,~* 2. Any non-SLE manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial,~* 3. Received \> 20 mg/day of prednisone equivalent for \> 7 days during the 30 days prior to screening,~* 4. Currently receiving or having received pulse dose corticosteroids or intravenous immunoglobulin (IVIg) within 3 months prior to screening,~* 5. Received cyclophosphamide within 3 months prior to screening,~* 6. Received a monoclonal antibody during the 6 months prior to screening,~* 7. Previously received an investigational treatment directed against IFNa,~* 8. Received B-cell depleting therapy (e.g. Rituximab) within 12 months~* 9. Received IV antibiotics during the 30 days prior to screening,~* 10. Significant electrocardiogram (ECG) abnormalities ,~* 11. Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator could represent active infection, latent tuberculosis or treatable manifestation of lupus,~* 12. Any laboratory abnormality that is clinically relevant~* 13. History of malignancy except completely excised basal cell carcinoma,~* 14. Congenital immune deficiency,~* 15. Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV),~* 16. Frequent recurrences of oral or genital herpes simplex lesions (≥ 6 / year),~* 17. Episode of shingles within one year of screening,~* 18. Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) or HBV (HBsAg, anti-HBc ab) positive,~* 19. Any current signs or symptoms of infection at entry,~* 20. Administration of any live vaccine within the 3 months prior to study entry~* 21. Planned use of any investigational or non-registered product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IFN-K 1 (Type: EXPERIMENTAL): IFN kinoid dose 1
- IFN-K-2 (Type: EXPERIMENTAL): IFN kinoid dose 2
- IFN-K 3 (Type: EXPERIMENTAL): IFN kinoid dose 3
- IFN-K 4 (Type: EXPERIMENTAL): IFN kinoid dose 4
- Saline (Type: PLACEBO_COMPARATOR): saline at same dose as IFN K

Based on this trial design, predict the completion outcome and termination type (if applicable).